Merck (NYSE: MRK) recently reported its Q3 results, with revenues and earnings exceeding the street estimates.
From drug pricing to reforming the drug regulatory process, Trump’s re-election has plenty of implications for the pharma ...
Barchart on MSN14d
Merck & Co. Stock: Is Wall Street Bullish or Bearish?With a market cap of $258 billion, Merck & Co., Inc. (MRK) is a global healthcare company, operating in the pharmaceutical and animal health sectors. Based in Rahway, New Jersey, Merck develops ...
NeuroBo Pharmaceuticals, Inc. , a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced the completion of the last patient last visit in its two-part, ...
"As a reminder, Part 1 of this Phase 2a trial is exploring DA-1241 compared to placebo, while Part 2 is investigating the efficacy of DA-1241 in combination with sitagliptin, a DPP-4 inhibitor ...
Yes, it is still Open Enrollment and a new modified Medicare Advantage plan has occurred. In September, subscribers for True ...
The negotiated list prices, announced in August ... blood thinners Xarelto and Eliquis and diabetes drugs Jardiance and Januvia. The nonpartisan Congressional Budget Office estimates that Medicare ...
The company saw strong sales from its top-selling cancer drug Keytruda, recently launched treatments and its animal health ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback